Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Simioli F, Nicoletta C, Valentino MR, Martino M, Annunziata A, Carannante N, Di Micco P, Fiorentino G. Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience. Healthcare (Basel) 2021;9:1108. [PMID: 34574882 DOI: 10.3390/healthcare9091108] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 07/29/2021] [Accepted: 08/11/2021] [Indexed: 12/14/2022] Open

For:	Simioli F, Nicoletta C, Valentino MR, Martino M, Annunziata A, Carannante N, Di Micco P, Fiorentino G. Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience. Healthcare (Basel) 2021;9:1108. [PMID: 34574882 DOI: 10.3390/healthcare9091108] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 07/29/2021] [Accepted: 08/11/2021] [Indexed: 12/14/2022] Open

Number

Cited by Other Article(s)

Libra A, Ciancio N, Sambataro G, Sciacca E, Muscato G, Marino A, Vancheri C, Spicuzza L. Use of Remdesivir in Patients Hospitalized for COVID-19 Pneumonia: Effect on the Hypoxic and Inflammatory State. Viruses 2023;15:2101. [PMID: 37896877 PMCID: PMC10612076 DOI: 10.3390/v15102101] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 10/13/2023] [Accepted: 10/14/2023] [Indexed: 10/29/2023] Open

Affiliation(s)

Alessandro Libra Regional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; (N.C.); (G.S.); (E.S.); (G.M.); (C.V.); (L.S.)
Nicola Ciancio Regional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; (N.C.); (G.S.); (E.S.); (G.M.); (C.V.); (L.S.)
Gianluca Sambataro Regional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; (N.C.); (G.S.); (E.S.); (G.M.); (C.V.); (L.S.)
Enrico Sciacca Regional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; (N.C.); (G.S.); (E.S.); (G.M.); (C.V.); (L.S.)
Giuseppe Muscato Regional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; (N.C.); (G.S.); (E.S.); (G.M.); (C.V.); (L.S.)
Andrea Marino Department of Biomedical and Biotechnological Sciences, Unit of Infectious Diseases, University of Catania, 95123 Catania, Italy;
Carlo Vancheri Regional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; (N.C.); (G.S.); (E.S.); (G.M.); (C.V.); (L.S.)
Lucia Spicuzza Regional Referral Centre for Rare Lung Disease, University Hospital “Policlinico-San Marco”, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy; (N.C.); (G.S.); (E.S.); (G.M.); (C.V.); (L.S.)

Collapse

De Vito A, Poliseno M, Colpani A, Zauli B, Puci MV, Santantonio T, Meloni MC, Fois M, Fanelli C, Saderi L, Fois A, Fiore V, Sotgiu G, Babudieri S, Lo Caputo S, Madeddu G. Reduced risk of death in people with SARS-CoV-2 infection treated with remdesivir: a nested case-control study. Curr Med Res Opin 2022;38:2029-2033. [PMID: 36170020 DOI: 10.1080/03007995.2022.2129801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]

Affiliation(s)

Andrea De Vito Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Mariacristina Poliseno S.C. Malattie Infettive, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Foggia, Italy
Agnese Colpani Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Beatrice Zauli Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Mariangela Valentina Puci Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Teresa Santantonio S.C. Malattie Infettive, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Foggia, Italy
Maria Chiara Meloni Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Marco Fois Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Chiara Fanelli Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Laura Saderi Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Alessandro Fois Unit of Respiratory Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Vito Fiore Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Giovanni Sotgiu Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Sergio Babudieri Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy
Sergio Lo Caputo S.C. Malattie Infettive, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Foggia, Foggia, Italy
Giordano Madeddu Unit of Infectious Diseases, Department of Clinical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy

Collapse

Di Micco P, Annunziata A, Fiorentino G. Editorial Comment on Special Issue—COVID-19 after One Year of Clinical Experience: Unexpected Clinical Presentations or Complications and Post-COVID-19 Clinical Features. Healthcare (Basel) 2022;10:healthcare10091715. [PMID: 36141327 PMCID: PMC9498340 DOI: 10.3390/healthcare10091715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Accepted: 09/05/2022] [Indexed: 11/20/2022] Open

Ticinesi A, Tuttolomondo D, Nouvenne A, Parise A, Cerundolo N, Prati B, Zanichelli I, Guerra A, Gaibazzi N, Meschi T. Co-Administration of Remdesivir and Azithromycin May Protect against Intensive Care Unit Admission in COVID-19 Pneumonia Requiring Hospitalization: A Real-Life Observational Study. Antibiotics (Basel) 2022;11:antibiotics11070941. [PMID: 35884195 PMCID: PMC9311950 DOI: 10.3390/antibiotics11070941] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Revised: 07/08/2022] [Accepted: 07/12/2022] [Indexed: 02/07/2023] Open

Affiliation(s)

Andrea Ticinesi Department of Medicine and Surgery, University of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (D.T.); (I.Z.); (A.G.); (T.M.) Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (A.N.); (A.P.); (N.C.); (B.P.) Correspondence:
Domenico Tuttolomondo Department of Medicine and Surgery, University of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (D.T.); (I.Z.); (A.G.); (T.M.) Department of Cardiology, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy;
Antonio Nouvenne Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (A.N.); (A.P.); (N.C.); (B.P.)
Alberto Parise Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (A.N.); (A.P.); (N.C.); (B.P.)
Nicoletta Cerundolo Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (A.N.); (A.P.); (N.C.); (B.P.)
Beatrice Prati Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (A.N.); (A.P.); (N.C.); (B.P.)
Ilaria Zanichelli Department of Medicine and Surgery, University of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (D.T.); (I.Z.); (A.G.); (T.M.)
Angela Guerra Department of Medicine and Surgery, University of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (D.T.); (I.Z.); (A.G.); (T.M.) Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (A.N.); (A.P.); (N.C.); (B.P.)
Nicola Gaibazzi Department of Cardiology, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy;
Tiziana Meschi Department of Medicine and Surgery, University of Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (D.T.); (I.Z.); (A.G.); (T.M.) Geriatric-Rehabilitation Department, Azienda Ospedaliero-Universitaria di Parma, Via Antonio Gramsci 14, 43126 Parma, Italy; (A.N.); (A.P.); (N.C.); (B.P.)

Collapse

Poliseno M, Gallo C, Cibelli DC, Minafra GA, Bottalico IF, Bruno SR, D’Errico ML, Montemurro L, Rizzo M, Barbera L, Custodero GE, La Marca A, Lo Muzio D, Miucci A, Santantonio TA, Lo Caputo S. Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic. Antibiotics (Basel) 2021;10:antibiotics10121477. [PMID: 34943688 PMCID: PMC8698274 DOI: 10.3390/antibiotics10121477] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 11/23/2021] [Accepted: 11/29/2021] [Indexed: 02/05/2023] Open

Affiliation(s)

Mariacristina Poliseno Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.) Correspondence: ; Tel.: +39-3471032012
Crescenzio Gallo Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy;
Donatella Concetta Cibelli Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Graziano Antonio Minafra Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Irene Francesca Bottalico Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Serena Rita Bruno Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Maria Luca D’Errico Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Laura Montemurro Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Marianna Rizzo Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Lucia Barbera Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Giacomo Emanuele Custodero Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Antonella La Marca Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Donatella Lo Muzio Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Anna Miucci Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Teresa Antonia Santantonio Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)
Sergio Lo Caputo Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (D.C.C.); (G.A.M.); (I.F.B.); (S.R.B.); (M.L.D.); (L.M.); (M.R.); (L.B.); (G.E.C.); (A.L.M.); (D.L.M.); (A.M.); (T.A.S.); (S.L.C.)

Collapse

Nayak B, Lal G, Kumar S, Das CJ, Saraya A, Shalimar. Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases. Front Cell Infect Microbiol 2021;11:753249. [PMID: 34760721 PMCID: PMC8573081 DOI: 10.3389/fcimb.2021.753249] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 10/04/2021] [Indexed: 01/08/2023] Open

Abstract

Background

Novel coronavirus SARS-CoV2 is evolving continuously with emergence of several variants of increasing transmission capabilities and pandemic potential. Generation of variants occurs through accumulation of mutations due to the RNA nature of viral genome, which is further enhanced by variable selection pressures of this ongoing pandemic. COVID-19 presentations of SARS-CoV2 are mainly pulmonary manifestations with or without mild gastrointestinal (GI) and hepatic symptoms. However, the virus has evolved beyond pulmonary manifestations to multisystem disorder due to systemic inflammation and cytokine storm. Definitive cause of acute or late onset of inflammation, infection in various organs, and host response to emerging variants lacks clarity and needs elucidation. Several studies have reported underlying diseases including diabetes, hypertension, obesity, cardio- and cerebrovascular disorders, and immunocompromised conditions as significant risk factors for severe form of COVID-19. Pre-existing liver and GI diseases are also highly predominant in the population, which can alter COVID-19 outcome due to altered immune status and host response. We aim to review the emerging variants of SARS-CoV2 and host response in patients with pre-existing liver and GI diseases.

Methods

In this review, we have elucidated the emergence and characteristic features of new SARS-CoV2 variants, mechanisms of infection and host immune response, GI and hepatic manifestation with radiologic features of COVID-19, and outcomes in pre-existing liver and GI diseases.

Key Findings

Emerging variants of concern (VOC) have shown increased transmissibility and virulence with severe COVID-19 presentation and mortality. There is a drastic swift of variants from the first wave to the next wave of infections with predominated major VOC including alpha (B.1.1.7, UK), beta (B.1.351, South Africa), gamma (B.1.1.28.1, Brazil), and delta (B1.1.617, India) variants. The mutations in the spike protein of VOC are implicated for increased receptor binding (N501Y, P681R) and immune escape (L452R, E484K/Q, T478K/R) to host response. Pre-existing liver and GI diseases not only have altered tissue expression and distribution of viral entry ACE2 receptor but also host protease TMPRSS2, which is required for both spike protein binding and cleavage to initiate infection. Altered immune status due to pre-existing conditions results in delayed virus clearance or prolonged viremia. Even though GI and hepatic manifestations of SARS-CoV2 are less severe, the detection of virus in patient’s stool indicates GI tropism, replication, and shedding from the GI tract. COVID-19-induced liver injury, acute hepatic decompensation, and incidences of acute-on-chronic liver failure may change the disease outcomes.

Conclusions

The changes in the spike protein of emerging variants, immunomodulation by viral proteins, and altered expression of host viral entry receptor in pre-existing diseases are the key determinants of host response to SARS-CoV2 and its disease outcome.

Collapse